SciELO - Scientific Electronic Library Online

SciELO - Scientific Electronic Library Online

Referencias del artículo

TAGLE, Rodrigo; GONZALEZ, Fernando  y  ACEVEDO, Mónica. Microalbuminuria y excreción urinaria de albúmina en la práctica clínica. Rev. méd. Chile [online]. 2012, vol.140, n.6, pp. 797-805. ISSN 0034-9887.  http://dx.doi.org/10.4067/S0034-98872012000600016.

    1. Keane WF, Eknoyan G. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. Am J Kidney Dis 1999; 33 (5): 1004-10. [ Links ]

    2. Montanes Bermúdez R, Gracia García S, Pérez Surribas D, Martínez Castelao A, Bover Sanjuan J. Consensus Document. Recommendations on assessing proteinuria during the diagnosis and follow-up of chronic kidney disease. Nefrología 2011; 31 (3): 331-45. [ Links ]

    3. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39 (2 Suppl 1): S1-266. [ Links ]

    4. Glassock RJ. Is the presence of microalbuminuria a relevant marker of kidney disease? Curr Hypertens Rep 2010; 12 (5): 364-8. [ Links ]

    5. Redon J. Measurement of microalbuminuria-what the nephrologist should know. Nephrol Dial Transplant 2006; 21 (3): 573-6. [ Links ]

    6. Cerasola G, Cottone S, Mule G. The progressive pathway of microalbuminuria: from early marker of renal damage to strong cardiovascular risk predictor. J Hypertens 2010; 28 (12): 2357-69. [ Links ]

    7. Zatz R, Meyer TW, Rennke HG, Brenner BM. Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy. Proc Natl Acad Sci USA 1985; 82 (17): 5963-7. [ Links ]

    8. Anderson S, Brenner BM. Pathogenesis of diabetic glomerulopathy: hemodynamic considerations. Diabetes Metab Rev 1988; 4 (2):163-77. [ Links ]

    9. Palatini P, Mormino P, Dorigatti F, Santonastaso M, Mos L, De Toni R, et al. Glomerular hyperfiltration predicts the development of microalbuminuria in stage 1 hypertension: the HARVEST. Kidney Int 2006; 70 (3): 578-84. [ Links ]

    10. Bianchi S, Bigazzi R, Campese VM. Microalbuminuria in essential hypertension: significance, pathophysiology, and therapeutic implications. Am J Kidney Dis. 1999; 34 (6): 973-95. [ Links ]

    11. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286 (4): 421-6. [ Links ]

    12. Satchell SC, Tooke JE. What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium? Diabetologia 2008; 51 (5): 714-25. [ Links ]

    13. Haraldsson B, Nyström J, Deen WM. Properties of the Glomerular Barrier and Mechanisms of Proteinuria. Physiological Reviews 2008; 88 (2): 451-87. [ Links ]

    14. Stehouwer CD. Endothelial dysfunction in diabetic nephropathy: state of the art and potential significance for non-diabetic renal disease. Nephrol Dial Transplant 2004; 19 (4): 778-81. [ Links ]

    15. Pedrinelli R, Penno G, Dell'Omo G, Bandinelli S, Giorgi D, Di Bello V, et al. Microalbuminuria and transcapillary albumin leakage in essential hypertension. Hypertension 1999; 34 (3): 491-5. [ Links ]

    16. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005; 67 (6): 2089-100. [ Links ]

    17. Eknoyan G, Hostetter T, Bakris GL, Hebert L, Levey AS, Parving HH, et al. Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). Am J Kidney Dis 2003; 42 (4): 617-22. [ Links ]

    18. Wachtell K, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 2003; 139 (11): 901-6. [ Links ]

    19. Gerber LM, Johnston K, Alderman MH. Assessment of a new dipstick test in screening for microalbuminuria in patients with hypertension. Am J Hypertens 1998; 11 (11 Pt 1): 1321-7. [ Links ]

    20. Mogensen CE, Vestbo E, Poulsen PL, Christiansen C, Damsgaard EM, Eiskjaer H, et al. Microalbuminuria and potential confounders. A review and some observations on variability of urinary albumin excretion. Diabetes Care 1995; 18 (4): 572-81. [ Links ]

    21. Gansevoort RT, Verhave JC, Hillege HL, Burgerhof JG, Bakker SJ, de Zeeuw D, et al. The validity of screening based on spot morning urine samples to detect subjects with microalbuminuria in the general population. Kidney Int Suppl 2005; 94: S28-35. [ Links ]

    22. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984; 310 (6): 356-60. [ Links ]

    23. Schmitz A, Vaeth M. Microalbuminuria: a major risk factor in non-insulin-dependent diabetes. A 10-year follow-up study of 503 patients. Diabet Med 1988; 5 (2): 126-34. [ Links ]

    24. Gall MA, Borch-Johnsen K, Hougaard P, Nielsen FS, Parving HH. Albuminuria and poor glycemic control predict mortality in NIDDM. Diabetes 1995; 44 (11): 1303-9. [ Links ]

    25. Miettinen H, Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects. Stroke 1996; 27 (11): 2033-9. [ Links ]

    26. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 1997; 157 (13): 1413-8. [ Links ]

    27. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63 (1): 225-32. [ Links ]

    28. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998; 317 (7160): 703-13. [ Links ]

    29. Middleton RJ, Foley RN, Hegarty J, Cheung CM, McElduff P, Gibson JM, et al. The unrecognized prevalence of chronic kidney disease in diabetes. Nephrol Dial Transplant 2006; 21 (1): 88-92. [ Links ]

    30. Glassock RJ. Debate: CON position. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial? Am J Nephrol 2010; 31 (5): 462-5; discussion 6-7. [ Links ]

    31. Kramer CK, Leitao CB, Pinto LC, Silveiro SP, Gross JL, Canani LH. Clinical and laboratory profile of patients with type 2 diabetes with low glomerular filtration rate and normoalbuminuria. Diabetes Care 2007; 30 (8): 1998-2000. [ Links ]

    32. Karalliedde J, Viberti G. Proteinuria in diabetes: bystander or pathway to cardiorenal disease? J Am Soc Nephrol 2010; 21 (12): 2020-7. [ Links ]

    33. Tsalamandris C, Allen TJ, Gilbert RE, Sinha A, Panagiotopoulos S, Cooper ME, et al. Progressive decline in renal function in diabetic patients with and without albuminuria. Diabetes 1994; 43 (5): 649-55. [ Links ]

    34. Gaede P, Tarnow L, Vedel P, Parving HH, Pedersen O. Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria. Nephrol Dial Transplant 2004; 19 (11): 2784-8. [ Links ]

    35. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345 (12): 870-8. [ Links ]

    36. Araki S-I, Haneda M, Koya D, Hidaka H, Sugimoto T, Isono M, et al. Reduction in Microalbuminuria as an Integrated Indicator for Renal and Cardiovascular Risk Reduction in Patients With Type 2 Diabetes. Diabetes 2007; 56 (6): 1727-30. [ Links ]

    37. Nelson RG, Bennett PH, Beck GJ, Tan M, Knowler WC, Mitch WE, et al. Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. Diabetic Renal Disease Study Group. N Engl J Med 1996; 335 (22): 1636-42. [ Links ]

    38. Newman DJ, Mattock MB, Dawnay AB, Kerry S, McGuire A, Yaqoob M, et al. Systematic review on urine albumin testing for early detection of diabetic complications. Health Technol Assess 2005; 9 (30): iii-vi, xiii-163. [ Links ]

    39. de Galan BE, Perkovic V, Ninomiya T, Pillai A, Patel A, Cass A, et al. Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol 2009; 20 (4): 883-92. [ Links ]

    40. Jerums G, Premaratne E, Panagiotopoulos S, Clarke S, Power DA, MacIsaac RJ. New and old markers of progression of diabetic nephropathy. Diabetes Res Clin Pract 2008; 82 Suppl 1: S30-7. [ Links ]

    41. Hoerger TJ, Wittenborn JS, Segel JE, Burrows NR, Imai K, Eggers P, et al. A Health Policy Model of CKD: 2. The Cost-Effectiveness of Microalbuminuria Screening. American journal of kidney diseases: the official journal of the National Kidney Foundation 2010; 55 (3): 46373. [ Links ]

    42. Palmer AJ, Valentine WJ, Chen R, Mehin N, Gabriel S, Bregman B, et al. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA. Nephrology Dialysis Transplantation 2008; 23 (4): 1216-23. [ Links ]

    43. Golan L, Birkmeyer JD, Welch HG. The Cost-Effectiveness of Treating All Patients with Type 2 Diabetes with Angiotensin-Converting Enzyme Inhibitors. Annals of Internal Medicine 1999; 131 (9): 660-7. [ Links ]

    44. Incerti J, Zelmanovitz T, Camargo JL, Gross JL, de Azevedo MJ. Evaluation of tests for microalbuminuria screening in patients with diabetes. Nephrol Dial Transplant 2005; 20 (11): 2402-7. [ Links ]

    45. Lepore G, Maglio ML, Nosari I, Dodesini AR, Trevisan R. Cost-effectiveness of two screening programs for microalbuminuria in type 2 diabetes. Diabetes Care 2002; 25 (11): 2103-4; [ Links ]

    46. Jager A, Kostense PJ, Ruhe HG, Heine RJ, Nijpels G, Dekker JM, et al. Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: five-year follow-up of the Hoorn Study. Arterioscler Thromb Vasc Biol 1999; 19 (3): 617-24. [ Links ]

    47. Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, Schroll M, Jensen JS. Urinary albumin excretion. An independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol 1999; 19 (8): 1992-7. [ Links ]

    48. Wachtell K, Olsen MH, Dahlof B, Devereux RB, Kjeldsen SE, Nieminen MS, et al. Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. J Hypertens 2002; 20 (3): 405-12. [ Links ]

    49. Ibsen H, Wachtell K, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. J Hypertens 2004; 22 (9): 1805-11. [ Links ]

    50. Olsen MH, Wachtell K, Bella JN, Palmieri V, Gerdts E, Smith G, et al. Albuminuria predicts cardiovascular events independently of left ventricular mass in hypertension: a LIFE substudy. J Hum Hypertens 2004; 18 (6): 453-9. [ Links ]

    51. Lambers Heerspink HJ, de Zeeuw D. Debate: PRO position. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial? Am J Nephrol 2010; 31 (5): 458-61; [ Links ]

    52. Bigazzi R, Bianchi S, Baldari D, Campese VM. Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens 1998; 16 (9): 1325-33. [ Links ]

    53. Viazzi F, Leoncini G, Conti N, Tomolillo C, Giachero G, Vercelli M, et al. Microalbuminuria is a predictor of chronic renal insufficiency in patients without diabetes and with hypertension: the MAGIC study. Clin J Am Soc Nephrol 2010; 5 (6): 1099-106. [ Links ]

    54. Clase CM, Gao P, Tobe SW, McQueen MJ, Grosshennig A, Teo KK, et al. Estimated glomerular filtration rate and albuminuria as predictors of outcomes in patients with high cardiovascular risk: a cohort study. Ann Intern Med 2011; 154 (5): 310-8. [ Links ]

    55. Hillege HL, Janssen WM, Bak AA, Diercks GF, Grobbee DE, Crijns HJ, et al. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med 2001; 249 (6): 519-26. [ Links ]

    56. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106 (14): 1777-82. [ Links ]

    57. Agrawal B, Berger A, Wolf K, Luft FC. Microalbuminuria screening by reagent strip predicts cardiovascular risk in hypertension. J Hypertens 1996; 14 (2): 223-8. [ Links ]

    58. Pontremoli R, Viazzi F, Sofia A, Tomolillo C, Ruello N, Bezante GP, et al. Microalbuminuria: a marker of cardiovascular risk and organ damage in essential hypertension. Kidney Int Suppl 1997; 63: S163-5. [ Links ]

    59. Hogan D, Lurbe E, Salabat MR, Redon J, Batlle D. Circadian changes in blood pressure and their relationships to the development of microalbuminuria in type 1 diabetic patients. Curr Diab Rep 2002; 2 (6): 539-44. [ Links ]

    60. Redon J, Williams B. Microalbuminuria in essential hypertension: redefining the threshold. J Hypertens 2002; 20 (3): 353-5. [ Links ]

    61. Pedrinelli R, Dell'Omo G, Di Bello V, Pontremoli R, Mariani M. Microalbuminuria, an integrated marker of cardiovascular risk in essential hypertension. J Hum Hypertens 2002; 16 (2): 79-89. [ Links ]

    62. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25 (6): 1105-87. [ Links ]

    63. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351 (19): 1941-51. [ Links ]

    64. Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370 (9590): 829-40. [ Links ]

    65. Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011; 364 (10): 907-17. [ Links ]

    66. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 2005; 45 (2): 198-202. [ Links ]

    67. Zuñiga C, Muller H, Flores M. Prevalencia de enfermedad renal crónica en centros urbanos de atención primaria. Rev Med Chile 2011; 139 (9). [ Links ]

    68. Icaza G, Núñez L, Marrugat J, Mujica V, Escobar MC, Jiménez AL, et al. Estimation of coronary heart disease risk in Chilean subjects based on adapted Framingham equations. Rev Med Chile 2009; 137 (10): 1273-82. [ Links ]

    69. Flores JC, Alvo M, Borja H, Morales J, Vega J, Zúñiga C, et al. Clinical guidelines on identification, management and complications of chronic kidney disease. Rev Med Chile 2009; 137 (1): 137-77. [ Links ]